Novogen Limited is on the Cruelty Free Investing list for exploiting animals because the company does animal testing for some of their medical analysis and clinical research.
The company stated in the following article that they conduct pre-clinical trials of their drugs on animals.
“Animal studies have confirmed that TRXE-009-1 is active against tumours growing in animals, but these studies used a non-clinical formulation.” Read the following article
Novogen Limited (Novogen) is an oncology biotechnology company, which is focused on developing cancer treatments. The Company is primarily engaged in pharmaceutical research and development. Novogen has two drug technology platforms (the Superbenzopyran (SBP) technology and Anti-tropomyosin (ATM)) yielding various drug candidates across a range of oncology indications. The Company’s product candidates include Cantrixil (TRX-E-002-1), Anisina (ATM-3507) and Trilexium (TRX-E-009-1). The Company’s target indication for Cantrixil is ovarian cancer, and Diffuse Intrinsic Pontine Glioma (DIPG) for Trilexium. The initial target pediatric indication for Anisina is neuroblastoma. Cantrixil is the lead development candidate arising from its SBP technology. Anisina is an approach to chemotherapy that targets the cancer cells’ actin cytoskeleton. Trilexium (TRX-E-009-1) is its second lead SBP drug candidate. It focuses on various cancers, including melanoma and prostate cancer. [Source: GoogleFinance]
Company Website: http://www.novogen.com